Burt Reynolds' hair loss was one of Hollywood's most openly discussed celebrity grooming secrets, with the actor famously acknowledging his use of toupées and hairpieces throughout his career. His candour helped normalise conversations about male hair loss — a condition affecting millions of men in the UK. This article uses Reynolds' story as a springboard to explore the common causes of hair loss in men, how it is diagnosed and assessed within UK healthcare, the treatment options available through the NHS and privately, and when it is appropriate to seek medical advice from a GP.

Burt Reynolds and Hair Loss: What Was Publicly Known

Burt Reynolds publicly acknowledged wearing hairpieces throughout his career, though no clinical diagnosis of his hair loss exists in the public domain; his openness helped reduce stigma around the condition.

Not sure if this is normal? Chat with one of our pharmacists →

Burt Reynolds, the iconic American actor known for films such as Smokey and the Bandit and Boogie Nights, was one of Hollywood's most recognisable faces from the 1970s onwards. Over the decades, his changing appearance — including his hairline and hair density — attracted considerable public attention. Reynolds was widely reported in mainstream press and acknowledged in interviews that he wore hairpieces and toupées throughout much of his career. His candour on the subject was considered relatively unusual for a major celebrity of his era.

It is important to emphasise that no clinical diagnosis relating to Reynolds' hair loss is available in the public domain. Any suggestion that his appearance was consistent with androgenetic alopecia is purely observational and should not be interpreted as a confirmed medical diagnosis.

Reynolds' willingness to discuss his use of hairpieces helped reduce some of the stigma associated with hair loss — a condition that can significantly affect self-esteem and psychological wellbeing. His story serves as a useful starting point for a broader, evidence-based conversation about the causes, assessment, and management of hair loss in men, within the context of UK healthcare guidance.

Common Causes of Hair Loss in Men

Androgenetic alopecia is the most common cause of male hair loss, but other causes include alopecia areata, telogen effluvium, tinea capitis, scarring alopecias, and medication-induced shedding, all requiring accurate diagnosis before treatment.

Hair loss in men is a widespread condition with several well-established causes. Understanding the underlying mechanism is essential for appropriate management.

Androgenetic alopecia (male-pattern baldness) is by far the most common cause, affecting approximately 50% of men by the age of 50. It is driven by a genetic sensitivity to dihydrotestosterone (DHT), a metabolite of testosterone. DHT binds to receptors in hair follicles, causing progressive miniaturisation, leading to shorter, finer hairs and eventually follicle dormancy. The pattern typically begins with a receding hairline and thinning at the crown.

Other notable causes include:

• Alopecia areata — an autoimmune condition in which the immune system attacks hair follicles, causing patchy hair loss

• Telogen effluvium — diffuse shedding triggered by physical or emotional stress, illness, nutritional deficiencies, or significant weight loss

• Tinea capitis — a fungal scalp infection more common in children but occasionally seen in adults; diagnosis may require scalp scraping and fungal microscopy or culture

• Traction alopecia — caused by prolonged tension on the hair from tight hairstyles

• Scarring alopecias (e.g., lichen planopilaris, frontal fibrosing alopecia, folliculitis decalvans) — a group of conditions in which inflammation leads to permanent follicle destruction; these warrant prompt dermatology referral to prevent irreversible hair loss

• Medication-induced hair loss — associated with drugs such as chemotherapy agents, anticoagulants, retinoids, and certain antihypertensives; the BNF provides a reference for medicines known to cause hair loss

Systemic conditions such as thyroid disorders, iron deficiency anaemia, coeliac disease, and lupus can also present with hair loss. Because the causes are varied and some are reversible, accurate diagnosis is important before initiating any treatment. Self-diagnosing and self-treating without professional assessment is not recommended, as it may delay identification of an underlying medical condition.

Further information is available from the NHS (Hair loss), the British Association of Dermatologists (BAD) patient information leaflets, and the Primary Care Dermatology Society (PCDS).

How Hair Loss Is Diagnosed and Assessed in the UK

Hair loss assessment in the UK begins with a GP consultation using clinical history and examination; the Hamilton–Norwood scale grades male-pattern baldness, and blood tests or dermoscopy may be arranged if a systemic cause is suspected.

In the UK, the initial assessment of hair loss typically begins with a consultation with a GP. A thorough history and physical examination are the cornerstones of diagnosis. The clinician will enquire about the pattern and duration of hair loss, family history, recent illnesses or stressors, dietary habits, and current medications — all of which can provide important diagnostic clues.

For suspected androgenetic alopecia, diagnosis is largely clinical. The Hamilton–Norwood scale is commonly used to grade the extent and pattern of male-pattern baldness, helping to guide treatment decisions and monitor progression over time.

In cases of diffuse shedding or where an underlying systemic cause is clinically suspected, targeted investigations may be arranged, including:

• Blood tests: full blood count (FBC), serum ferritin, thyroid function tests (TFTs), and coeliac serology where indicated

• Hormone testing (e.g., testosterone, sex hormone-binding globulin) is not routinely required in men with typical male-pattern hair loss; it should be reserved for cases where clinical features suggest an endocrine disorder

• Scalp examination: using dermoscopy, a non-invasive technique that allows detailed visualisation of the scalp and follicles

• Scalp scraping and fungal microscopy or culture: when tinea capitis is suspected

• Scalp biopsy: occasionally performed in specialist settings to differentiate between scarring and non-scarring alopecias

Referral to a consultant dermatologist via the NHS is appropriate where there is diagnostic uncertainty, suspected scarring alopecia, rapidly progressive hair loss, inflammatory tinea capitis (kerion), or where the condition affects children. Early specialist referral for scarring alopecia is particularly important, as permanent follicle destruction may occur if treatment is delayed.

Relevant UK guidance includes NICE Clinical Knowledge Summaries (CKS) on alopecia areata and fungal scalp infection, PCDS guidance on androgenetic alopecia, and BAD patient information resources. Patients should be reassured that many forms of hair loss are treatable, particularly when identified early, and that a clear diagnosis is the essential first step.

Treatment Options Available Through the NHS and Privately

Topical minoxidil (OTC) and finasteride 1 mg (private prescription) are the most evidence-based treatments for androgenetic alopecia; finasteride carries MHRA safety warnings and is not routinely available on the NHS.

Treatment for hair loss in the UK depends on the underlying cause and the individual's preferences. Not all treatments are available on the NHS; some are considered cosmetic rather than medically necessary.

For androgenetic alopecia, the two most evidence-based treatments are:

• Topical minoxidil: available over the counter (OTC) at pharmacies in the UK as a 2% or 5% solution or 5% foam. It prolongs the anagen (growth) phase of the hair cycle and increases follicular size. Consistent use for at least three to six months is required before improvement is visible, and hair loss typically resumes if treatment is discontinued. Refer to the electronic Medicines Compendium (eMC) Summary of Product Characteristics (SmPC) for full prescribing information.

Oral minoxidil is a separate matter: it is a prescription-only medicine (POM) in the UK and is not licensed for hair loss (it is licensed for severe hypertension under the brand name Loniten). Its use for alopecia is therefore off-label and should only be initiated and monitored by a specialist with appropriate cardiovascular safety assessment. Potential risks include hypotension, reflex tachycardia, fluid retention, and oedema. Oral minoxidil is not available over the counter and should not be self-administered without medical supervision.

• Finasteride 1 mg daily: a 5-alpha reductase inhibitor that blocks the conversion of testosterone to DHT, thereby reducing follicular miniaturisation. It is licensed for men only (typically aged 18–41) and is available on private prescription in the UK. It is not routinely available on the NHS for androgenetic alopecia. Results typically take three to six months to become apparent, and continued use is required to maintain benefit.

• Important safety information — please read carefully: The MHRA has issued Drug Safety Updates advising that finasteride is associated with the following adverse effects, which patients should be aware of before starting treatment:
• Sexual side effects: reduced libido, erectile dysfunction, and ejaculation disorders. In a small number of men, these effects have been reported to persist after stopping the drug (sometimes referred to as post-finasteride syndrome); causality remains under investigation.
• Psychiatric effects: depression, anxiety, and — rarely — suicidal thoughts. Patients should stop taking finasteride and seek immediate medical advice if they experience mood changes, depression, or thoughts of self-harm.
• Potential effects on fertility: finasteride may affect semen quality; men wishing to father children should discuss this with their prescriber.
• Rare male breast changes: including breast tenderness, enlargement, or nipple discharge; any such changes should be reported to a doctor promptly.
• Handling precautions: pregnant women or women who may become pregnant must not handle crushed or broken finasteride tablets, as the active ingredient can be absorbed through the skin and may harm a male foetus. A patient alert card is available and should be provided at the time of prescribing. Refer to the MHRA Drug Safety Update and the eMC SmPC for finasteride 1 mg for full safety information. Suspected adverse reactions should be reported via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk or via the Yellow Card app.

For alopecia areata, treatment options include potent topical corticosteroids, intralesional steroid injections, and — in more extensive cases — immunotherapy. For severe alopecia areata, the JAK inhibitor ritlecitinib is now recommended by NICE (Technology Appraisal, 2024) and may be available through specialist NHS services for eligible patients meeting the defined criteria. Patients should be assessed by a consultant dermatologist to determine suitability.

Surgical options such as hair transplantation (follicular unit extraction or follicular unit transplantation) are available privately and can produce natural-looking, permanent results in suitable candidates. These are not routinely funded by the NHS.

Wigs and hairpieces remain a practical and widely used option. The NHS may provide a wig voucher for patients experiencing hair loss due to a medical condition or treatment such as chemotherapy.

For prescribing details, interactions, and monitoring requirements, refer to the BNF entries for finasteride and minoxidil, and to the relevant eMC SmPCs.

When to Speak to a GP About Hair Loss

Seek GP advice promptly if hair loss is sudden, patchy, accompanied by scalp symptoms, or associated with systemic symptoms; scarring alopecia and inflammatory tinea capitis require urgent referral to prevent permanent damage.

Many men delay seeking medical advice about hair loss, often attributing it to normal ageing or genetics. Whilst gradual thinning consistent with male-pattern baldness may not require urgent attention, there are several circumstances in which speaking to a GP promptly is advisable.

Contact your GP if you notice:

• Sudden or rapid hair loss over a short period

• Patchy or irregular hair loss rather than gradual, diffuse thinning

• Hair loss accompanied by scalp redness, scaling, itching, or pain

• Hair loss alongside other symptoms such as fatigue, unexplained weight changes, or skin changes — which may suggest a systemic condition such as thyroid disease or iron deficiency

• Hair loss that appears to be related to a new medication

• Significant psychological distress, anxiety, or low mood associated with hair loss

Seek urgent GP or dermatology assessment if you suspect:

• Scarring alopecia (e.g., lichen planopilaris, frontal fibrosing alopecia) — permanent follicle destruction can occur rapidly without treatment

• Inflammatory tinea capitis or kerion — requires prompt antifungal treatment to prevent scarring

• Rapidly progressive hair loss of uncertain cause

For those experiencing distress related to hair loss, psychological support is a legitimate part of holistic care. GPs can refer patients to appropriate services, and NHS Talking Therapies (previously known as IAPT) provides access to evidence-based psychological therapies in England for those whose mental health is affected; a service finder is available on the NHS website. The patient charity Alopecia UK also offers peer support and information.

If you experience any suspected side effects from a hair loss treatment, report these via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk or via the Yellow Card app.

Experiencing these side effects? Our pharmacists can help you navigate them →

In summary, hair loss is a common but clinically significant condition. Whether prompted by the experience of public figures such as Burt Reynolds or by personal concern, seeking timely, evidence-based advice from a healthcare professional is always the recommended course of action.

Key UK resources:

• NHS: Hair loss (alopecia) — nhs.uk

• MHRA Drug Safety Update: Finasteride — gov.uk/mhra

• NICE CKS: Alopecia areata; Fungal scalp infection (tinea capitis)

• NICE Technology Appraisal: Ritlecitinib for severe alopecia areata (2024)

• British Association of Dermatologists (BAD) patient information — bad.org.uk

• Primary Care Dermatology Society (PCDS) — pcds.org.uk

• Alopecia UK — alopecia.org.uk

• MHRA Yellow Card scheme — yellowcard.mhra.gov.uk

Frequently Asked Questions